Stereotactic body radiotherapy using the CyberKnife (R) system in the treatment of patients with liver metastases: state of the art

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F18%3AA1901Z0G" target="_blank" >RIV/61988987:17110/18:A1901Z0G - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.2147/OTT.S165878" target="_blank" >http://dx.doi.org/10.2147/OTT.S165878</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.2147/OTT.S165878" target="_blank" >10.2147/OTT.S165878</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Stereotactic body radiotherapy using the CyberKnife (R) system in the treatment of patients with liver metastases: state of the art

Popis výsledku v původním jazyce

Background: The management of patients with liver metastases presents a challenging problem in clinical oncology. Patients with limited involvement of the liver may be suitable for surgical resection or local ablative techniques. Stereotactic body radiotherapy (SBRT) presents an emerging new technology that has shown high efficacy in ablating tumors at various disease sites. Methods: A comprehensive literature search was performed to identify articles in regard to the SBRT in the treatment of patients with liver metastases. Results: SBRT allows for the delivery of high-dose radiation in few fractions to the tumor with extreme accuracy, while minimizing the damage to normal surrounding tissue. The CyberKnife (R) system is an image-guided robotic system that delivers SBRT, tracks tumors during respiration, and automatically adjusts treatment for any patient movement. The most frequently used indications for CyberKnife (R) therapy are &lt;= 5 liver metastases with maximum tumor sizes of 6 cm, no extrahepatic disease, good performance status, and adequate hepatic functions. Local control rates range from 70%-100% at 1 year and from 60%-90% at 2 years. Severe toxicity related to SBRT is uncommon - grade three side effects occur in less than 5% of cases. Despite excellent local control rates, out-of-field metastatic progression (out-of-field hepatic metastases and extrahepatic metastases) develops in a substantial proportion of patients after SBRT. Therefore, it seems essential to improve the selection of patients with liver metastases for SBRT. Conclusion: The CyberKnife (R) system presents an effective minimally invasive treatment modality for patients with hepatic oligometastases who are not suitable candidates for radical liver resection. The available data suggest that liver metastases can be treated by CyberKnife therapy with very low toxicity and excellent local control rates.

Název v anglickém jazyce

Stereotactic body radiotherapy using the CyberKnife (R) system in the treatment of patients with liver metastases: state of the art

Popis výsledku anglicky

Background: The management of patients with liver metastases presents a challenging problem in clinical oncology. Patients with limited involvement of the liver may be suitable for surgical resection or local ablative techniques. Stereotactic body radiotherapy (SBRT) presents an emerging new technology that has shown high efficacy in ablating tumors at various disease sites. Methods: A comprehensive literature search was performed to identify articles in regard to the SBRT in the treatment of patients with liver metastases. Results: SBRT allows for the delivery of high-dose radiation in few fractions to the tumor with extreme accuracy, while minimizing the damage to normal surrounding tissue. The CyberKnife (R) system is an image-guided robotic system that delivers SBRT, tracks tumors during respiration, and automatically adjusts treatment for any patient movement. The most frequently used indications for CyberKnife (R) therapy are &lt;= 5 liver metastases with maximum tumor sizes of 6 cm, no extrahepatic disease, good performance status, and adequate hepatic functions. Local control rates range from 70%-100% at 1 year and from 60%-90% at 2 years. Severe toxicity related to SBRT is uncommon - grade three side effects occur in less than 5% of cases. Despite excellent local control rates, out-of-field metastatic progression (out-of-field hepatic metastases and extrahepatic metastases) develops in a substantial proportion of patients after SBRT. Therefore, it seems essential to improve the selection of patients with liver metastases for SBRT. Conclusion: The CyberKnife (R) system presents an effective minimally invasive treatment modality for patients with hepatic oligometastases who are not suitable candidates for radical liver resection. The available data suggest that liver metastases can be treated by CyberKnife therapy with very low toxicity and excellent local control rates.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

ONCOTARGETS AND THERAPY

ISSN

1178-6930

e-ISSN

—

Svazek periodika

—

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

NZ - Nový Zéland

Počet stran výsledku

7

Strana od-do

4685-4691

Kód UT WoS článku

000441748900001

EID výsledku v databázi Scopus

2-s2.0-85057987951